Insider transaction details
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) reported that Chief Financial Officer Ali Asif sold 24,765 shares of common stock on March 26, 2026. The shares were sold at $104.24 apiece, generating approximately $2.58 million in proceeds. That sale price was just under the stock's 52-week high of $105.69. Separately, the company's shares are currently quoted at $98.94 and have produced a one-year return of 100%.
Simultaneous option exercises
On the same date as the sale, Asif also exercised stock options to acquire a total of 24,765 shares of Protagonist common stock. The exercises came from two distinct option grants: 19,500 shares were obtained by exercising options with an exercise price of $19.19, and 5,265 shares were obtained by exercising options with an exercise price of $12.17. The total value attributed to those acquired shares, based on the exercise details provided, was $438,280.
Market valuation context
An InvestingPro analysis included with the filing indicates that the stock appears overvalued relative to its Fair Value estimate. That assessment was noted alongside the transaction disclosure but no additional valuation metrics were supplied in the disclosure itself.
Regulatory milestone and commercial outlook
Protagonist has recently received FDA approval for Icotyde (icotrokinra), its treatment for moderate-to-severe plaque psoriasis. The approval covers use in adults and in adolescents aged 12 years and older. Under an existing collaboration agreement, Johnson & Johnson will commercialize the drug. The clearance was reported to have arrived earlier than anticipated, a timing detail cited as supportive of the therapy's commercial prospects.
Analyst reactions
Following the approval, several research firms adjusted their price targets for Protagonist. Clear Street raised its target to $104 and maintained a Buy rating. Barclays lifted its target to $119 while retaining an Overweight rating. Jefferies increased its price target to $121 and reiterated a Buy rating. Truist Securities kept a Buy rating with a $110 target and highlighted Protagonist's shift toward operating as a commercial company. These revisions were presented as part of the market response to the regulatory milestone.
ProPicks and model-driven coverage
The company and its stock have also been evaluated by model-driven tools referenced in the disclosure materials. One such tool, described as an AI-driven selection process, assesses companies using more than 100 financial metrics and notes historical examples of strong performers in its universe. Readers interested in whether PTGX is included in such strategies were directed to additional resources referenced in the filing.
This report presents the transaction details, the related option exercises, published valuation commentary, the FDA approval for Icotyde, and subsequent analyst target adjustments based on the information disclosed by the company and associated reports.